First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

Bexion Pharmaceuticals Announces the Opening of Phase I Part 3

 FOR IMMEDIATE RELEASE

Covington, KY ~ February 22, 2019 – Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer. This trial was designed to determine the maximum tolerated dose of BXQ-350 and to characterize its safety and pharmacokinetics.

The Phase I Part 1 study showed that BXQ-350 was well tolerated at all five doses tested with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy. Part 2 tested the highest dose in an additional 36 solid tumor patients. Preliminary data support a safe and tolerable drug profile. The purpose of Part 3 will be to explore safety, and additional indications in rare and gastrointestinal tumors.

“By enrolling patients in Part 3, we hope to gain a better understanding of the potential of BXQ-350 in treating cancer,” stated Dr. Ray Takigiku, Founder and CEO of Bexion.

 

About Bexion Pharmaceuticals

Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. BXQ-350 has demonstrated pre-clinical antitumor effects in vitro and in vivo, particularly in brain and other solid tumors, including those that may lead to brain metastases.   Bexion has completed multi-site first-in-human Phase 1 Parts 1 and 2 clinical studies of BXQ-350 for solid tumors and gliomas. A Phase 1 Part 3 expansion phase study is currently enrolling patients.

For more information, visit www.bexionpharma.com.

 

Media Contact

Margaret van Gilse
859.757.1652 ●
mvangilse@bexionpharma.com

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Bexion’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Bexion has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Bexion’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that Bexion’s compounds may not successfully complete pre-clinical or clinical testing,or be granted regulatory approval to be sold and marketed in the United States or elsewhere. You should not place undue reliance on any forward-looking statements. Bexion undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

 

 

2019-02-28T23:15:28+00:00 February 22nd, 2019|